Johannes Bigenzahn
152 posts




News from our research line on signaling in cancer: We found a new fragment engaging RAS which is capable of inducing association with LZTR1: Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3LZTR1 E3 Ligase KRAS Complex pubs.acs.org/doi/10.1021/ac…




Hier ist sie, die letzte. Die Allerletzte.




In @JExpMed, Wei Wei, @DrBenNeel et al @nyulangone perform CRISPR/Cas9 screens for SHP2 inhibitor resistance. Deletion of resistance genes causes ERK activation & cross-resistance to FLT3-ITD/BCR-ABL inhibition in FLT3-ITD or BCR-ABL–driven AML lines. bit.ly/3ZiNtto




The study “Metabolic drug survey highlights cancer cell dependencies and vulnerabilities” was published in the journal @NatureComms on 14 December 2021. nature.com/articles/s4146…
